Long Noncoding RNA RFPL1S-202 Inhibits Ovarian Cancer Progression by Downregulating the IFN-β/STAT1 Signaling.

Siyu Liu,Xiyi Chen,Ke Huang,Xueyou Xiong,Yaqian Shi,Xusu Wang,Xinxing Pan,Yu Cong,Yu Sun,Lili Ge,Juan Xu,Xuemei Jia
DOI: https://doi.org/10.1016/j.yexcr.2022.113438
IF: 4.145
2023-01-01
Experimental Cell Research
Abstract:Background: RFPL1S was first identified as one of the pseudogenes located in the intrachromosomal duplications within 22q12-13. Our previous study found that one of the predicted transcripts of lncRNA RFPL1S, ENST00000419368.1 (GRCh37/hg19), also named as RFPL1S-202 in Ensembl website, is significantly down -regulated in the chemoresistant ovarian cancer cells. However, its function and underlying mechanism have not been studied. Methods: Quantitative Real-time PCR was used to analyze the expression. Cell Counting Kit-8, transwell, flow cytometry analysis and tail vein injected mouse model were used to test the function. RNA-sequencing, RNA pull down, western blot, ELISA and RNA-Binding Protein Immunoprecipitation were performed for studying the mechanism. 5 ' and 3 ' rapid amplification of complementary DNA ends were performed to analyze the full length of RFPL1S-202. Results: RFPL1S-202 is significantly downregulated in epithelial ovarian cancer tissues and cell lines. Gain-and loss-of-function study indicated that RFPL1S-202 could enhance cisplatin or paclitaxel in cytotoxicity, inhibit cell proliferation, invasion and migration of ovarian cancer cells in vitro, and inhibit the liver metastasis of ovarian cancer cells in vivo. Mechanistically, RFPL1S-202 could physically interact with DEAD-Box Helicase 3 X-linked (DDX3X) protein, and decrease the expression of p-STAT1 and the IFN inducible genes by increasing the m6A modification of IFNB1. RFPL1S-202 is a spliced and polyadenylated non-coding RNA with a full length of 1071 bp. Conclusions: Our study suggested that the predicted lncRNA RFPL1S-202 exerts a tumor-suppressive function in oarian cancer chemoresistance and progression by interacting with DDX3X and down-regulating the IFN-beta-STAT1 signaling pathway.
What problem does this paper attempt to address?